Beilin Le
乐贝林
Beilin Le is a managing director at Gaorong Ventures, where he focuses on healthcare investments with a stated emphasis on backing companies with global innovation capabilities and competitive strength . He led Gaorong's investment in ProfoundBio starting in 2021 and publicly endorsed the company's $1.8 billion acquisition by Genmab in 2024, framing it as validation of Gaorong's strategy of helping portfolio companies reach the international stage . Earlier in his tenure at Gaorong, he held the title of executive director and moderated panels on innovative drug R&D, drawing on his background in the sector to convene founders and executives from biotech companies including Fubei Bio, Anda Pharma, and ProfoundBio . He has also been involved in Gaorong's medtech coverage, hosting discussions with companies such as Hejeya Medical and Qitan Tech .
AI-generated — may contain errors, please verify.
Coverage
Rongbao | Multiple autonomous driving, nuclear fusion, gaming, and innovative drug companies raise hundreds of millions of RMB in funding
From commercial deployment to world-first breakthroughs, innovation never stands still.
高榕创投·Warm congratulations to Saint Bella on its successful Hong Kong IPO. Gaorong Ventures was an early investor and has been a long-term partner throughout.
Hong Kong's stock market welcomes the "first share of family quality care."
高榕创投·Congratulations to Mirxes on its successful listing on the Hong Kong Stock Exchange's Main Board — Gaorong Ventures was its earliest institutional investor.
A leading provider of molecular cancer screening products and services.
高榕创投·Gaorong Ventures in Conversation with Hejeya and Qitan Tech: How Innovative Medical Devices "Cross the Razor's Edge"
"When you meet a mountain, you cut a path through it; when you meet a river, you build a bridge across it."
高榕创投·Genmab Acquires ProfoundBio for $1.8 Billion | Gaorong Ventures News
Accelerate the development and unlock the full potential of ADC therapies.
高榕创投·From Big Pharma to Biotech: Four Industry Leaders on How Innovative Drugs Can Balance Speed and Quality | Ronghui
Speed matters, but getting it right matters more.
高榕创投·Robotics, SaaS, and innovative drug sectors close new funding rounds; chips and medical devices unveil major new products | Rongbao · August
Differentiated innovation and global opportunities.
高榕创投·
